Neurophet, which is pursuing a listing on the KOSDAQ, secured nearly 7 trillion won in subscription deposits from general investors.
On the 16th, Neurophet announced that it had gathered subscription deposits totaling 6.7296 trillion won from general investor subscriptions conducted over two days from the 15th to that day.
A total of 279,248 applications were received, with a competition ratio of 1,922.75 to 1.
Founded in 2016, Neurophet is a specialist company in artificial intelligence (AI)-based brain disease imaging analysis solutions. It supplies imaging analysis solutions to domestic and international hospitals and pharmaceutical companies, generating 2.2 billion won in sales last year.
Ban Jun-gil, CEO of Neurophet, noted, "Investors highly evaluated Neurophet's unique technology in the field of brain disease imaging analysis and the scalability of its medical AI business."
Previously, a total of 2,444 domestic and foreign institutional investors participated in Neurophet's demand forecasting, with a competition ratio of 1,087.6 to 1.
Meanwhile, Neurophet is set to go public on the KOSDAQ market on the 25th after the settlement.